부산대학교 도서관

This article presents a case series conducted in Greece on the use of baricitinib, a JAK inhibitor, for the treatment of alopecia areata (AA). The study enrolled 12 AA patients who had previously tried various treatments without success. The patients received baricitinib as monotherapy and were followed up monthly. After 24 weeks of treatment, 90% of the patients had responded, with 50% classified as complete responders. The study found that baricitinib had a favorable safety profile, with mild adverse events that did not require dosage adjustment or discontinuation. The authors suggest that baricitinib shows promise as a therapeutic option for moderate-to-severe AA, but further research is needed to validate these findings. [Extracted from the article]